Stay updated on Pembrolizumab for Lung Cancer Prevention Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Lung Cancer Prevention Clinical Trial page.

Latest updates to the Pembrolizumab for Lung Cancer Prevention Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the IMPRINT-Lung pembrolizumab study, including its study details, eligibility criteria, locations, outcomes, and documents.SummaryDifference57%

- Check16 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the study record remains inaccessible due to a 403 error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page content.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe site footer revision indicator changed from v3.7.0 to v3.7.1 while the study page remains unavailable with a 403 Forbidden message.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with an access-denied screen. The additions include the 403 text and HTML header, while the detailed study content is not visible.SummaryDifference20%

Stay in the know with updates to Pembrolizumab for Lung Cancer Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Lung Cancer Prevention Clinical Trial page.